PET/MR Imaging for COVID-19
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new method of capturing brain images using both PET and MR imaging simultaneously. It aims to understand brain metabolism and blood flow in individuals with and without a history of COVID-19. Participants will receive an injected radiotracer (a safe, tiny amount of radioactive substance) to capture detailed images. Ideal candidates have proof of a COVID-19 test conducted within the last 20 to 180 days and have experienced low radiation exposure in the past year. As an unphased study, this trial offers a unique opportunity to contribute to groundbreaking research on brain imaging techniques.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this imaging protocol is safe?
Research shows that the radiotracer used in this study has FDA approval for other purposes, indicating prior safety testing in humans. In earlier studies, participants received a small amount of this radiotracer, which was generally well-tolerated with few side effects.
In this trial, participants will receive an injection of the radiotracer and then undergo a PET/MR scan. This process uses a PET device inside an MRI machine to capture detailed body images. The imaging is non-invasive, meaning it doesn't involve surgery or entering the body.
No specific unwanted side effects have been noted for this radiotracer in this trial. However, as with any medical procedure, risks may exist. Discuss any concerns with the clinical trial team before participating.12345Why are researchers excited about this trial?
Researchers are excited about the PET/MR Imaging for COVID-19 trial because it explores advanced imaging techniques that could revolutionize how we understand and diagnose COVID-19. Unlike traditional imaging methods like X-rays or CT scans, this trial uses a PET insert combined with MRI, which may offer deeper insights into how COVID-19 affects the body at a molecular level. This combination could potentially detect changes in tissues and organs with greater precision, helping to identify complications earlier and tailor treatments more effectively. By using radiopharmaceuticals, researchers hope to visualize the disease's progression and impact in ways never seen before, paving the way for more personalized and timely interventions.
What evidence suggests that this imaging protocol is effective for studying COVID-19?
Research has shown that PET (Positron Emission Tomography) scans, which use substances called radiotracers, effectively reveal activity levels in different body parts. A common radiotracer, 18F-FDG, identifies areas with high activity. Studies using this method on COVID-19 patients have found changes in activity levels, enhancing understanding of how the infection affects the body. In this trial, participants will receive an injection of a radiopharmaceutical and undergo imaging with PET/MR technology. The trial includes two groups: COVID-19 positive/infected participants and COVID-19 negative/uninfected participants. PET scans have proven helpful in detecting and evaluating the long-term effects of COVID-19. This technique, when combined with MRI (Magnetic Resonance Imaging), provides a detailed view of both the brain's structure and function. Although this study is in the early stages, the technique shows promise for understanding the effects of COVID-19.15678
Are You a Good Fit for This Trial?
This trial is for adults over 21 who've had a low radiation exposure in the past year and are healthy enough for imaging studies. They must have proof of COVID-19 testing done between 20 to 180 days before the scan but can't join if they're pregnant, nursing, allergic to PET radiotracers, or have non-MRI safe surgeries or implants.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants are injected with radiopharmaceutical and imaged on the 3T PETMR with PET insert
Follow-up
Participants are monitored for any immediate post-imaging effects
What Are the Treatments Tested in This Trial?
Interventions
- Injected radiotracer with PET Insert
Trial Overview
The study tests a new brain-focused PET insert used inside an MR scanner on people with and without past COVID-19 infection. It aims to create protocols for simultaneous PET/MR images that show both brain function (metabolism/perfusion) and structure.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
5 participants will be recruited, injected with radiopharmaceutical, and imaged on the 3T PETMR with PET insert.
5 participants will be recruited, injected with radiopharmaceutical, and imaged on the 3T PETMR with PET insert.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stanford University
Lead Sponsor
Citations
Pilot Study for PET/MR Imaging of Covid-19
Participants will receive a small quantity of an FDA approved radiotracer. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be ...
First-in-human immunoPET imaging of COVID-19 ...
The mean injected radiotracer activity was 18.8 MBq (0.51 mCi), with a range ... effective radiation dose) were acquired prior to the later timepoint PET scans.
3.
researchgate.net
researchgate.net/publication/340499386_Nuclear_medicine_in_SARS-CoV-2_pandemia_18F-FDG-PETCT_to_visualize_COVID-19Nuclear medicine in SARS-CoV-2 pandemia: 18F-FDG ...
... 18 F-labelled fluorodeoxyglucose ( 18 F-FDG) is the most commonly used radiotracer in PET/CT imaging; it shows metabolic activity in ...
18F-FDG-PET/CT in SARS-CoV-2 infection and its sequelae
Recent studies have been appearing collecting the findings of 18 F-FDG-PET/CT in long COVID-19 or persistent COVID-19 state as well as the alterations caused ...
5.
studypages.com
studypages.com/s/a-study-of-the-experimental-petct-radiotracer-18f-avb6-binding-peptide-after-covid-19-coronavirus-infection-935076/A Study of the Experimental PET/CT Radiotracer "18F-avb6 ...
We will inject the radiotracer and let you rest quietly for about an hour. We will then position you on your back on the scanner table with cushions to make ...
Effects of COVID-19 vaccination on FDG-PET/CT imaging
Several studies have reported FDG avidity in enlarged axillary lymph nodes as a specific feature of FDG-PET/CT imaging after COVID-19 vaccination.
FDA Approves Required Updated Warning in Labeling of ...
The observed risk of myocarditis and pericarditis following vaccination with mRNA COVID-19 vaccines has been highest in males 12 through 24 years of age.
COVID vaccination and post-infection cancer signals
The predominance of case-level observations and early population-level data demonstrates an early phase of potential safety-signal detection.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.